SPOREGEN LIMITED is a biotechnology company based at The London BioScience Innovation Centre (LBIC) in London.
SPOREGEN is focused on four areas.
1. Clostridium difficile: we have developed a unique prophylactic and therapeutic approach for C. difficile infection.
2. Probiotics: we identify and develop Bacillus, heat stable, spore probiotic formulations. This includes progression to GRAS status and a number of these have now been licenced including HU58 and HU36.
3. Prophylactic approaches to COVID-19 including SPOR-COV, a unique mucosal immune modulator, and SPORCOVAX, a mucosal vaccine.
4. Contracts: focusing primarily on in vivo evaluations of C. difficile interventions.
Company Details
- Employees
- 4
- Founded
- 2012
- Address
- 2 Royal College Street, London,england Nw1 0nh,united Kingdom
- Phone
- 44-(0)1784-443760
- in****@****gen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sporegen.com/
- Keywords
- Probiotics, Medical Foods, Clostridium difficile, Bacillus spore formers, mucosal vaccines, animal vaccines.
- HQ
- London, England
Sporegen Limited Questions
Sporegen Limited's helpline number is 44-(0)1784-443760
Sporegen Limited's website is http://www.sporegen.com/
Sporegen Limited's LinkedIn profile is https://uk.linkedin.com/company/sporegen-limited
Sporegen Limited has
4 employees.
View email and phone details for 4
employees at Sporegen Limited.
Sporegen Limited's industry is
Biotechnology Research
Sporegen Limited's top competitors are
Ellipses Pharma,
Small Pharma,
Quell Therapeutics,
Eden Genetics Ltd,
Orchard Therapeutics - U.s.,
Aviadobio,
Ori Biotech,
Synthace,
Bactobio,
Labgenius Therapeutics.
Sporegen Limited's support email address is info@sporegen.com
Sporegen Limited's categories are Biotechnology Research
Sporegen Limited's founding year is 2012
